Combined atezolizumab (anti-PD-L1) and bevacizumab (anti-angiogenesis) showed significant improvements in prolonging OS rates when compared with traditional first-line HCC treatments with sorafenib or lenvatinib (38). Here, CD274 is linked to hepatocellular carcinoma.